Monopar Therapeutics (MNPR) News Today $20.10 +0.39 (+1.98%) (As of 11/22/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Jones Trading raises Monopar Therapeutics target to $37November 21 at 6:56 PM | uk.investing.comMonopar Therapeutics Gains Buy Rating Following Strategic Agreement and Promising Phase III Results for Wilson’s Disease TreatmentNovember 20 at 3:45 AM | markets.businessinsider.comMonopar Therapeutics price target raised to $37 from $9 at JonesResearchNovember 20 at 3:45 AM | markets.businessinsider.comWhat is HC Wainwright's Estimate for MNPR FY2024 Earnings?Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at HC Wainwright increased their FY2024 earnings estimates for Monopar Therapeutics in a research note issued to investors on Monday, November 11th. HC Wainwright analyst S. Lee now expects that the company will earn ($1November 14, 2024 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Given New $22.00 Price Target at HC WainwrightHC Wainwright boosted their price objective on shares of Monopar Therapeutics from $6.00 to $22.00 and gave the stock a "buy" rating in a report on Monday.November 11, 2024 | marketbeat.comTransformative Licensing Acquisition Drives Buy Rating for Monopar TherapeuticsNovember 11, 2024 | markets.businessinsider.comMonopar Therapeutics price target raised to $22 from $6 at H.C. WainwrightNovember 11, 2024 | markets.businessinsider.comMonopar Therapeutics Inc.: Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsNovember 8, 2024 | finanznachrichten.deMonopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsNovember 8, 2024 | markets.businessinsider.comMonopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent DevelopmentsNovember 8, 2024 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) CFO Acquires $25,187.50 in StockOctober 31, 2024 | insidertrades.comMonopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common StockOctober 30, 2024 | globenewswire.comMonopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common StockOctober 28, 2024 | globenewswire.comMonopar Therapeutics Inc. Announces Proposed Public Offering of Common StockOctober 28, 2024 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Sees Significant Drop in Short InterestMonopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 49,900 shares, a drop of 55.6% from the September 30th total of 112,400 shares. Currently, 2.8% of the company's stock are short sold. Based on an average daily trading volume, of 1,110,000 shares, the short-interest ratio is currently 0.0 days.October 27, 2024 | marketbeat.comIndividual investors are Monopar Therapeutics Inc.'s (NASDAQ:MNPR) biggest owners and were rewarded after market cap rose by US$40m last weekOctober 26, 2024 | finance.yahoo.comMarketBeat Week in Review – 10/21- 10/25 (MNPR)Equities had a mixed week, but the tech-heavy NASDAQ powered to an all-time high; big tech earnings and key economic reports could bring more volatilityOctober 26, 2024 | marketbeat.comWhat's Going On With Monopar Therapeutics Shares Friday?October 26, 2024 | msn.comMonopar Therapeutics (NASDAQ:MNPR) Shares Gap Down - Time to Sell?Monopar Therapeutics (NASDAQ:MNPR) Shares Gap Down - Time to Sell?October 25, 2024 | marketbeat.comMonopar Therapeutics Skyrockets 400% on Licensing DealMonopar Therapeutics (NASDAQ: MNPR) surged over 400% on Thursday after securing a licensing deal with AstraZeneca for a once-terminated Phase 3 drug.October 25, 2024 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Sets New 52-Week High - Should You Buy?Monopar Therapeutics (NASDAQ:MNPR) Reaches New 1-Year High - Here's WhyOctober 24, 2024 | marketbeat.comMonopar Shares Rise on AstraZeneca Licensing DealOctober 24, 2024 | marketwatch.comMonopar Shares Surge on AstraZeneca Licensing Deal -- UpdateOctober 24, 2024 | marketwatch.comMonopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug CandidateOctober 24, 2024 | markets.businessinsider.comMonopar Therapeutics Unveils Promising Radiopharmaceutical DataOctober 22, 2024 | markets.businessinsider.comMonopar Therapeutics presents data from radiopharma program based on MNPR-101October 22, 2024 | markets.businessinsider.comMonopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024October 22, 2024 | globenewswire.comMonopar Therapeutics Expands Portfolio with New Patent FilingOctober 16, 2024 | finance.yahoo.comMonopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and LinkersOctober 15, 2024 | globenewswire.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Sees Large Decrease in Short InterestMonopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totalling 112,400 shares, a drop of 82.8% from the September 15th total of 652,500 shares. Approximately 6.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 806,900 shares, the short-interest ratio is presently 0.1 days.October 10, 2024 | marketbeat.comMonopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer TrialOctober 8, 2024 | finance.yahoo.comMonopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced CancersOctober 7, 2024 | markets.businessinsider.comMonopar Therapeutics (NASDAQ:MNPR) Stock, Short Interest ReportOctober 2, 2024 | benzinga.comMonopar Therapeutics (NASDAQ:MNPR) Stock, Insider Trading ActivityOctober 1, 2024 | benzinga.comMONOPAR THERAP. NEW (1IY0.MU)September 12, 2024 | ca.finance.yahoo.comMonopar Shares Rise After Clinical Data on Cancer TreatmentSeptember 12, 2024 | marketwatch.comMonopar Therapeutics Inc.: Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-ZrSeptember 12, 2024 | finanznachrichten.deMonopar Therapeutics Soars Over Announcement Of Positive Data From MNPR-101-Zr Phase 1 TrialSeptember 12, 2024 | markets.businessinsider.comWhy Monopar Therapeutics (MNPR) Stock Is Skyrocketing TodaySeptember 12, 2024 | msn.comMonopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-ZrSeptember 12, 2024 | globenewswire.comMonopar to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 5, 2024 | finance.yahoo.comMonopar Regains Compliance with Nasdaq Minimum Bid Price RuleAugust 27, 2024 | globenewswire.comMonopar Therapeutics Inc.: Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced CancersAugust 21, 2024 | finanznachrichten.deMonopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced CancersAugust 21, 2024 | globenewswire.comBuy Rating Affirmed for Monopar Therapeutics on Clinical Progress and Strategic Financial PositioningAugust 16, 2024 | markets.businessinsider.comMonopar Therapeutics Inc. (1IY0.F)August 15, 2024 | au.finance.yahoo.comMonopar Therapeutics Inc.: Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-ZrAugust 14, 2024 | finanznachrichten.deMonopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-ZrAugust 14, 2024 | globenewswire.com1IY.SG,0P0001LR0T,0 (1IY.SG)August 13, 2024 | uk.finance.yahoo.comMonopar Therapeutics Inc.: Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent DevelopmentsAugust 9, 2024 | finanznachrichten.de Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. MNPR Media Mentions By Week MNPR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNPR News Sentiment▼0.720.49▲Average Medical News Sentiment MNPR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNPR Articles This Week▼42▲MNPR Articles Average Week Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vistagen Therapeutics News Citius Pharmaceuticals News Daré Bioscience News Merrimack Pharmaceuticals News Aquestive Therapeutics News Canopy Growth News KalVista Pharmaceuticals News Akebia Therapeutics News Larimar Therapeutics News Tango Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNPR) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
